

Humanized Monoclonal Antibody (IgM) against SARS-CoV-2 Spike Protein-1 Receptor-binding Domain (S1RBD)

Catalog Number: 41A253

Size: 100 µL

Species: Human

Introduction

The SARS-CoV-2 glycosylated spike (S) protein highly exposed on the viral surface is a major determinant for virus binding and invasion into host cells, which is a main target for neutralization antibody. The receptor-binding domain (RBD) in SARS-CoV-2 S protein is responsible for binding to human and bat angiotensin-converting enzyme 2 (ACE2) receptors.

Production:

The cDNA encoding the highly variable region of the antibody recognizing S1RBD were identified by phage display library, fused with the Fc fragment of human IgM, and expressed in Chinese Hamster Ovary (CHO) cells.

Formulation and Storage

Sterile PBS, pH 7.4. Store at -80°C. Avoid repeated freeze-thaw cycles.

Application/Usage

This product is intended use for in vitro diagnostics as the quality control. Optimal concentration/dilution should be determined by the end user.

Concentration

0.4 mg/ml (determined by BCA-based quantification)

Reference

1. Shajahan A, *et al.* (2020) Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. bioRxiv, <https://doi.org/10.1101/2020.04.01.020966>.
2. Walls, A C, *et al.* (2020) Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*, 181(2), 281-292.e6. <https://doi.org/10.1016/j.cell.2020.02.058>.